Skip to content
medxy logo Medxy AI
  • Specialties
    • Allergy & Immunology
    • Anesthesiology
    • Cardiology
    • Critical Care
    • Dermatology
    • Diabetes & Endocrinology
    • Emergency Medicine
    • Family Medicine & Nutrition
    • Gastroenterology
    • General Surgery
    • Hematology-Oncology
    • HIV/AIDS
    • Infectious Diseases
    • Internal Medicine
    • Nephrology
    • Neurology
    • Nursing & care
    • OB/GYN & Women’s Health
    • Oncology
    • Ophthalmology
    • Orthopedics
    • Otorhinolaryngology
    • Pathology & Lab Medicine
    • Pediatrics
    • Plastic Surgery
    • Psychiatry
    • Public Health
    • Radiology
    • Respiratory
    • Rheumatology
    • Urology
  • Clinical Updates
  • Medical News
  • iDoctor
  • Specialties
    • Allergy & Immunology
    • Anesthesiology
    • Cardiology
    • Critical Care
    • Dermatology
    • Diabetes & Endocrinology
    • Emergency Medicine
    • Family Medicine & Nutrition
    • Gastroenterology
    • General Surgery
    • Hematology-Oncology
    • HIV/AIDS
    • Infectious Diseases
    • Internal Medicine
    • Nephrology
    • Neurology
    • Nursing & care
    • OB/GYN & Women’s Health
    • Oncology
    • Ophthalmology
    • Orthopedics
    • Otorhinolaryngology
    • Pathology & Lab Medicine
    • Pediatrics
    • Plastic Surgery
    • Psychiatry
    • Public Health
    • Radiology
    • Respiratory
    • Rheumatology
    • Urology
  • Clinical Updates
  • Medical News
  • iDoctor
  • facebook.com
  • twitter.com
  • t.me
  • instagram.com
  • youtube.com
Subscribe
  • Home
  • basal insulin
Efficacy and Safety of Tirzepatide Added to Basal Insulin in Chinese Patients with Type 2 Diabetes: Insights from the SURPASS-CN-INS Phase 3 Trial
Posted inDiabetes & Endocrinology news

Efficacy and Safety of Tirzepatide Added to Basal Insulin in Chinese Patients with Type 2 Diabetes: Insights from the SURPASS-CN-INS Phase 3 Trial

Posted by MedXY By MedXY 11/17/2025
This phase 3 study demonstrates that adding tirzepatide to basal insulin significantly improves glycemic control in Chinese patients with type 2 diabetes, with a manageable safety profile.
Read More
Once-Weekly Insulin Efsitora: A Paradigm Shift in Initiation of Basal Insulin for Type 2 Diabetes
Posted inClinical Updates Diabetes & Endocrinology news Specialties

Once-Weekly Insulin Efsitora: A Paradigm Shift in Initiation of Basal Insulin for Type 2 Diabetes

Posted by MedXY By MedXY 08/09/2025
Weekly fixed-dose insulin efsitora demonstrated noninferiority to daily glargine in reducing HbA1c in insulin-naïve type 2 diabetes, with fewer hypoglycemic events and simpler dose adjustment.
Read More
  • Robotic vs Laparoscopic Cholecystectomy: No Outcome Advantage Across Disease Severity Grades
  • Molecular Complexity of Endometrial Cancer: How Biomarker Patterns Vary Across Tumor Stages, Histology, and Molecular Subtypes
  • Evidence Gaps in Maternity Guidelines: RCOG Green-Top Guidelines Show Limited Health Equity Considerations in High-Quality Recommendations
  • Flash Glucose Monitoring Fails to Improve Glycemic Control but Reduces Large-for-Gestational-Age Risk in Gestational Diabetes
  • Beyond Simple Quantification: How AI and Tumor-Stroma Ratio Are Redefining Prognosis Prediction in Hepatocellular Carcinoma
  • About us
  • Contact us
  • MedXY story
  • Privacy Policy
  • Subscribe Now!
  • 账号

  • English
  • 日本語
  • Tiếng Việt
  • 中文

Alzheimer's disease artificial intelligence atrial fibrillation biomarkers breast cancer Cardiology cardiovascular disease cardiovascular risk chronic kidney disease clinical trial clinical trials critical care depression diabetes epidemiology exercise health heart failure Hypertension immunotherapy inflammation MASLD mental health metformin Mortality myocardial infarction nutrition obesity older adults oncology Pediatrics precision medicine Pregnancy prevention prostate cancer public health randomized clinical trial randomized trial SGLT2 inhibitors stroke targeted therapy type 1 diabetes type 2 diabetes weight loss women's health

Your health, we care

Copyright 2026 — Medxy AI. All rights reserved.
Scroll to Top
Sign in